BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that the technology transfer for NurOwn® manufacturing at Catalent’s facility has been finalized. NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.

Catalent entered into a partnership with Brainstorm in 2020 to provide CGMP clinical supply of NurOwn, in anticipation of the product candidate’s potential regulatory approval. NurOwn will be manufactured at Catalent’s world-class 32,000 square-foot cell therapy manufacturing facility in Houston, Texas.

“The successful completion of this technology transfer with Catalent is an important step in establishing manufacturing preparedness for NurOwn,” said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics. “The manufacturing of cellular therapies such as NurOwn is complex, and requires careful planning and very specific expertise. We are very pleased with the progress we have made with our partner Catalent, which has industry-leading capabilities in this area.”

Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, “Our extensive experience in cell therapy development and scale-up was key to the completion of this technology transfer to our state-of-the-art cell therapy facility in Houston, Texas. We look forward to continuing our partnership with BrainStorm and are committed to enabling the advancement of their autologous stem cell therapy product candidate toward a potential future commercial launch.”

Read the full press release here